Top Story Today
America Invented CAR-T. Now It's Playing Catch-Up.
China now runs more CAR-T clinical trials than the United States, with over 300 registered as of early 2024, and it enrolls patients faster thanks to structural advantages. The cost gap is staggering: a CAR-T treatment runs north of $370,000 in the U.S. versus $70,000 to $200,000 in China. Meanwhile, NIH grant approval rates dropped to about 13% in FY2025 (down roughly 30% from prior levels), and the number of funded investigators fell by nearly 2,000. With China's total R&D spending reaching 96% of the U.S. level in purchasing power parity terms, the gene therapy market projected to hit $78 billion by the mid-2030s, and Asia-Pacific growing at 29% annually, the innovation center of gravity is shifting faster than most realize.
Why it matters: This isn't just a scorecard. If U.S. research funding stalls while China accelerates, American patients could end up waiting longer for therapies that Chinese patients already have access to, reshaping the strategic calculus for biotech investors and R&D leaders worldwide.
Read more →Deals and Strategy
The Syringe Giant That Just Bet $200M It Can Outgrow Needles
Embecta, the century-old insulin syringe maker, is acquiring UK auto-injector company Owen Mumford for up to $200 million. The real prize is Aidaptus, a next-gen auto-injector platform that adapts to variable syringe fill levels. With the auto-injector market growing at 13% to 16% annually and GLP-1 injectables booming, Embecta is pivoting from flip-phone-era syringes to the drug delivery devices pharma actually wants.
Read more →Devices and Regulatory
MiniMed's New Insulin Pump Ditched Its Screen Entirely
Half the size of its predecessor and completely screenless: that's MiniMed's Flex insulin pump, which just scored FDA 510(k) clearance. The device runs entirely through a smartphone app and still holds a full 300-unit reservoir. Launching weeks after MiniMed's Nasdaq IPO, the Flex intensifies its fight with Insulet's Omnipod in a $7 billion pump market where discretion is becoming the deciding factor.
Read more →